Biomarker Study: Impact of Single Doses of LY2979165 and LY2140023 on the Ketamine-Challenge Pharmacological MRI Assay in Healthy Male Subjects.

Trial Profile

Biomarker Study: Impact of Single Doses of LY2979165 and LY2140023 on the Ketamine-Challenge Pharmacological MRI Assay in Healthy Male Subjects.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2013

At a glance

  • Drugs MP 101 Mediti Pharma (Primary) ; Pomaglumetad methionil (Primary) ; Ketamine
  • Indications Bipolar disorders; Schizophrenia
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Most Recent Events

    • 29 Aug 2012 Status changed from recruiting to discontinued, according to an Eli Lilly media release.
    • 02 Jul 2012 Planned end date changed from 1 Mar 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 02 May 2012 Planned end date changed from 1 Jan 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top